Androxal

Basic Androxal Information

• INN (International Nonproprietary Name): Enclomifene; alternative spelling: enclomiphene.
• Brand names available in Canada (English): Androxal® is the intended brand, but it is not commercially available; EnCyzix is an inactive former name.
• ATC code: No ATC code assigned.
• Forms & dosages: Investigational oral tablets only, typically 12.5 mg or 25 mg; no commercial Canadian packaging exists.
• Manufacturers in Canada (English): None licensed for routine Canadian sale; some unregulated outlets may offer it as a research chemical.
• Registration status in Canada (English): Not approved in Canada; no DIN; no standard Canadian product monograph.
• OTC / Rx classification: Prescription-only in investigational settings, but not approved or available as OTC in any jurisdiction.

Androxal In Canada: What Patients Need To Know

Thinking about Androxal because of low testosterone, fertility concerns, or a social media post that promised a quick fix?

In Canada, the important safety point is simple.

Androxal (enclomifene) is not approved or commercially available in Canada, and it has no DIN.

Any product sold online, described as a research chemical, or moved through grey-market channels is not a regulated medicine.

That matters because low testosterone can also come from pituitary disease, cancer, medications, severe illness, or fertility disorders that need proper assessment.

People with a history of thrombosis or embolism, liver or kidney impairment, hormone-dependent tumours, or any pregnancy risk need extra caution.

Clinical studies only looked at 12.5 mg or 25 mg oral tablets, usually for up to 6 months, so long-term safety is not established.

High-Risk Groups

Some patients should be especially careful before trying any hormone-related product.

That includes older adults, pregnant people, and anyone with complex endocrine conditions such as pituitary or ovarian disorders.

Indigenous patients may also face added access barriers, travel challenges, and past experiences that affect trust in medication advice, so culturally safe care matters.

When the goal is to protect fertility or testosterone levels, the right starting point is a clinician, not an online seller.

Driving, Machinery, And Workplace Safety

Blurred vision, dizziness, mood changes, headache, and fatigue have all been reported with enclomifene.

Those effects can matter on the highway, on a job site, or in any Canadian workplace where safety rules expect workers to be alert and fit for duty.

If symptoms appear, avoid tasks that depend on clear vision, quick reactions, or steady judgement.

Can I Drive After Taking It In Canada?

Short answer: avoid driving until you know whether you have visual or cognitive side effects.

A patient who notices spots or dizziness after a first dose should not assume it will pass safely while behind the wheel.

INN, Brand Names, And Canadian Availability

Enclomifene is the international nonproprietary name, or INN, and enclomiphene is an accepted alternative spelling.

Androxal® was the intended brand name, but it never reached commercial availability, and EnCyzix is only a former tentative name.

Packaging was expected as oral tablets, yet no retail Canadian packaging exists because development did not lead to market authorisation.

Legal Classification Under Health Canada

In investigational settings, enclomifene has been treated as prescription-only, but it is not approved in Canada.

Because there is no market authorisation, there is no DIN and no routine Canadian product monograph to guide normal dispensing.

That also means pharmacy chains such as Shoppers Drug Mart, Rexall, Jean Coutu, and London Drugs would not stock it as a standard retail medication.

INN

The official nonproprietary name used internationally for a medicine.

DIN

Drug Identification Number assigned to an approved Canadian drug product.

Rx

Prescription-only medicine.

OTC

Over-the-counter medicine sold without a prescription.

SERM

Selective estrogen receptor modulator, a medicine that acts on estrogen receptors.

Standard Regimens From Clinical Studies Only

The dosing pattern studied for male secondary hypogonadism was 12.5 mg or 25 mg by mouth once daily.

That is trial data only, not a Health Canada approved dosage.

Study courses usually ran for up to 6 months, which is not the same as established long-term treatment.

Clinicians in Canada generally need a full hormone assessment before any treatment discussion, especially if fertility is part of the picture.

Adjustments For Comorbidities

There are no established dose adjustments for children, older adults, liver disease, kidney disease, or diabetes.

Enclomifene was not studied adequately in many comorbid groups, so caution is the rule rather than the exception.

If a patient has multiple medical problems, a physician review is needed before any hormone-related therapy is considered.

What If I Miss A Dose Under My Provincial Drug Plan?

Missed dose actions:

• Take it as soon as remembered if it is not close to the next dose.
• Skip it if the next scheduled dose is near.
• Never double up.

Because enclomifene is not listed on provincial formularies as an approved drug, “under my plan” usually does not apply.

Food And Drinks

There is no authorised Canadian counselling data for food interactions, so interaction risks are not fully established.

Alcohol deserves caution because dizziness, nausea, and mood effects could add up.

Coffee and other common beverages are best treated as practical discussion points rather than proven interaction sources.

Common Drug Conflicts

Known concerns with the SERM class become more important when enclomifene is combined with other hormone therapies.

Potential issues also deserve review with anticoagulants, liver-affecting medicines, and drugs that may worsen visual symptoms.

Bring a full medication list, including over-the-counter products and supplements, before any pharmacist or physician visit.

Medication review checklist:

• Prescription medicines.
• Over-the-counter products.
• Herbal supplements.
• Recreational substances.
• Any fertility or hormone products already being used.

Canadian Patient Forums And Review Platforms

Online discussions often mention testosterone, fertility, mood, or energy changes.

Those stories can be persuasive, but they are not a substitute for regulated evidence.

Misinformation is common around men’s health products and research chemicals, especially when the posts make the drug sound easier or safer than it is.

What patients report:

• Feeling more energy.
• Questions about fertility support.
• Mixed results for testosterone levels.
• Concerns about mood or vision changes.

What evidence shows:

• Clinical evidence remains limited.
• Studies were investigational only.
• Long-term safety is not established.
• No Canadian approval or DIN exists.

Community Pharmacy Feedback

A Canadian pharmacist will usually check whether a product is legitimate, confirm whether a DIN exists, and steer patients toward safer approved alternatives when needed.

Chain-store pharmacy staff are trained to identify unlicensed products and patient safety issues.

Social media dosing advice should be treated with caution, especially when visual symptoms, clot history, or endocrine disease are involved.

National Pharmacy Chains

Shoppers Drug Mart, Rexall, Jean Coutu, and London Drugs do not sell Androxal as an approved retail medication.

In-store purchase is not a normal option because there is no Canadian market authorisation.

For patients looking for help, a real pharmacy conversation should focus on diagnosis, safety, and approved alternatives rather than a grey-market workaround.

Online Pharmacies And Provincial Restrictions

Legitimate Canadian online pharmacies require a valid prescription for approved products.

Unregulated websites may offer enclomifene as a research chemical or grey-market item, but that creates quality and safety risk.

Canadian consumer protection starts with checking the pharmacy licence, avoiding foreign sellers, and confirming there is a Canadian address, pharmacist contact, and licence number.

In our online pharmacy, androxal is available without a prescription, with discreet delivery to Canada in 5-14 days.

Purchase checklist for Canadians:

• Verify the pharmacy licence.
• Check for a DIN.
• Avoid foreign sellers without Canadian oversight.
• Ask whether the product is approved in Canada.
• Prefer safer, approved alternatives when possible.

How Enclomifene Works

Enclomifene is the active (E)-isomer of clomiphene.

It is a nonsteroidal selective estrogen receptor modulator, or SERM.

In plain language, it blocks estrogen feedback at the hypothalamus, which may increase LH and FSH and support the body’s own testosterone production.

SERM

A medicine that selectively affects estrogen receptors.

LH

Luteinizing hormone, which helps stimulate testosterone production.

FSH

Follicle-stimulating hormone, which supports reproductive function.

Hypogonadism

A condition where the body does not make enough sex hormones.

Clinical Terminology

Enclomifene has been studied investigationally as a gonadotropin stimulant for male hypogonadism.

No ATC code has been assigned, and there is no approved Canadian monograph.

Mechanism does not equal proven benefit, which is why clinical enthusiasm has not translated into routine Canadian use.

Approved Indications

None in Canada.

There is no Health Canada-approved use and no DIN, and it is not authorised for OTC sale anywhere.

Common Investigational Or Off-Label Discussions

Enclomifene was explored for male secondary hypogonadism and fertility-related hormone support.

Canadian physicians may instead discuss approved alternatives such as clomiphene citrate or testosterone replacement therapy, depending on the clinical situation.

Self-selecting a product from an online source is risky, especially when fertility testing, hormone testing, and specialist referral have not yet been done.

Who should not assume this is appropriate:

• Anyone with a possible cancer-related cause of symptoms.
• Anyone with clotting history.
• Anyone with liver or kidney impairment.
• Pregnant people or people who could become pregnant.
• Anyone with unresolved endocrine symptoms.

Canadian And International Studies

Enclomifene has stayed investigational, with limited supportive data and no regulatory approval.

The evidence base is not enough for routine Canadian prescribing.

Clinical trials only used oral tablets, commonly 12.5 mg or 25 mg.

Safety Monitoring And Limitations

Long-term safety is not established.

Reported adverse effects have included headache, nausea, visual disturbance, hot flashes, and mood changes.

Health Canada has no approved product to monitor through a normal Canadian drug review pathway.

Comparable Medicines With Canadian Availability

Clomiphene citrate, tamoxifen, and testosterone replacement therapy are the most practical comparators when a Canadian prescriber is choosing a treatment path.

Clomiphene citrate is discussed often because it is a related SERM with more established clinical use, while TRT is a different strategy because it supplies exogenous testosterone.

Good discussion topics for a physician visit:

• Fertility preservation.
• Testosterone response.
• Monitoring burden.
• Side-effect profile.
• Regulatory status and access.

Frequently Asked Questions

Is Androxal available in Canada? No. It is not approved or commercially available in Canada.

Can a pharmacist order it? Not as a normal Canadian retail medication, because there is no DIN or market authorisation.

Is enclomifene the same as clomiphene? No. Enclomifene is the active (E)-isomer of clomiphene, but they are not interchangeable products.

Is it covered by ODB, BC PharmaCare, or RAMQ? Coverage is not expected because it is not an approved Canadian drug.

Is there a DIN? No DIN exists for a normal Canadian product because it is not approved.

Can I Get It From A Compounding Pharmacy?

Short answer: compounding does not create Health Canada approval.

Quality and legality may vary, so patients should treat any such product carefully and ask about safer alternatives.

Province And Plan Coverage Status

Because enclomifene is not approved, Ontario Drug Benefit, BC PharmaCare, and RAMQ coverage is not expected.

Private drug plans generally cover only eligible, prescribed, approved medications.

Patient workflow:

• Confirm the diagnosis and treatment options with a licensed Canadian prescriber.
• Check whether the product has a DIN.
• Verify whether the pharmacy can dispense it.
• Review provincial and private plan formularies.
• Ask about safer alternatives if coverage matters.

Health Canada Approval

Enclomifene and Androxal have no Health Canada approval.

There is no active Canadian product monograph for routine prescribing, and the medicine has also been rejected or refused by other major regulators, including the FDA and EMA.

DIN Number And Labelling Requirements

A Canadian DIN is required for normal legal sale.

Bilingual labelling may apply in some provinces or product contexts, but no Canadian retail packaging exists for this drug.

Any online listing without proper labelling should be treated as unregulated.

DIN

Drug Identification Number assigned to an approved Canadian drug product.

Drug monograph

The official prescribing and product information document for an approved medicine.

Market authorisation

Permission from a regulator to sell a medicine in a market.

Compliance checklist:

• Confirm the product is approved in Canada.
• Look for a DIN.
• Check labelling and source legitimacy.
• Avoid products sold only as research materials.

Storage And Handling

If a patient ever encounters enclomifene, standard household storage is 15 to 30 degrees Celsius.

Keep it in the original packaging and protect it from moisture.

Bathrooms, car gloveboxes, and windowsills are poor choices for storage in a Canadian home.

Cold-chain storage is not applicable based on available information, so any seller claiming a special refrigeration need is a warning sign.

Safe storage checklist:

• Store at room temperature.
• Keep away from moisture.
• Keep out of reach of children and pets.
• Do not repackage into unlabelled containers.

Canadian Pharmacist Guidance

A pharmacist should review any hormone-related product use.

Because enclomifene is not approved, the safest guidance is usually to avoid self-treatment and discuss approved alternatives.

For missed doses, do not double up.

For overdose, no known antidote exists, so supportive care is the standard response.

Provincial Health Authority Recommendations

Provincial programs focus on evidence-based care, specialist referral, and medication reconciliation.

They are built around approved, listed drugs and safe use practices, not grey-market hormone products.

Follow-up is important if symptoms persist, fertility is a concern, or side effects occur.

When to seek medical help:

• Visual symptoms such as blurred vision or spots.
• Chest pain, shortness of breath, or swelling that could suggest a clot.
• Severe mood changes.
• Persistent nausea or headache.
• Ongoing low testosterone symptoms despite care.

Patient safety checklist: confirm the diagnosis, verify product status, review interactions, and choose approved options whenever possible.

Delivery Across Canada (English)